<DOC>
	<DOCNO>NCT02787486</DOCNO>
	<brief_summary>In January 2007 , American Congress Obstetricians Gynecologists ( ACOG ) revise guideline recommend physician ethically obligate fully inform pregnant woman screen fetal chromosomal abnormality include biochemical screening test invasive procedure CVS amniocentesis available , regardless age . Further , entirely patient decide whether wish screen fetal chromosomal abnormality without judgment physician . Noninvasive laboratory-developed test ( LDTs ) detect abnormal amount maternal fetal DNA expectant mother 's blood sample ( know circulate cell-free DNA ) available . These LDTs clear approve U.S. Food Drug Administration ( FDA ) . Although LDTs date subject U.S. FDA regulation , certification laboratory require Clinical Laboratory Improvement Amendments ( CLIA ) ensure quality validity test . To sample collection study obtain whole blood specimen pregnant subject use development prenatal assay assist screen fetal genetic abnormality , infectious disease , blood group type detection circulate cell-free DNA extract maternal plasma .</brief_summary>
	<brief_title>Expanded Noninvasive Genomic Medical Assessment : The Enigma Study</brief_title>
	<detailed_description>Eligible subject provide write informed consent basic demographic clinical data collect . Study procedures involve collection 50 mL whole blood one monthly clinic visit ( â‰¥25 day apart ) pregnant woman ( 18 54 yrs age ) carry single fetus 8 22 week gestational age inclusive .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Aneuploidy</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Klinefelter Syndrome</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<mesh_term>Chromosome Deletion</mesh_term>
	<criteria>Subject willing provide inform consent comply study procedure Pregnant female , 18 54 year age carry singleton fetus 8 22 week gestational age Willing provide study blood sample accordance protocol Willing allow access medical record collect pregnancy outcome information Willing provide consent release fetal karyotype invasive procedure ( CVS amniocentesis ) perform pregnancy Subject know risk one following : fetal gene chromosome abnormality ( e.g. , T21 , T18 , T13 , microdeletion syndrome , sex chromosome abnormality ) congenital fetal infection ( e.g . toxoplasmosis , syphilis , HIV , rubella , CMV , HSV ) irregular blood group antigens ( subject father baby ) condition amenable noninvasive prenatal test single gene disorder ( e.g. , CF , sickle cell , Fragile X ) No fetal heart activity detect Mother father know chromosomal abnormality ( include know balanced translocation ) Women active history malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Down syndrome</keyword>
	<keyword>Edwards syndrome</keyword>
	<keyword>Patau syndrome</keyword>
	<keyword>Klinefelter syndrome</keyword>
	<keyword>DiGeorge syndrome</keyword>
	<keyword>Chromosome Deletion</keyword>
	<keyword>Aneuploidy</keyword>
</DOC>